Catalyst partner DyDo submits NDA in Japan for FIRDAPSE; milestone payment triggered

CATALYST PHARMACEUTICALS, INC.

DyDo Pharma submitted NDA to PMDA for FIRDAPSE (amifampridine) 10 mg for LEMS in Japan.
Submission based on favorable interim data after six months of the safety-phase registration study.
Upon acceptance of NDA filing, Catalyst due JPY 200M (~$1.4M USD) milestone payment from DyDo.
Territorial rights automatically expand to Asia, Central/South America; plans underway for global partnerships.
PMDA review period expected to be a minimum of nine months from submission date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.